Walleye Capital LLC Invests $1.52 Million in CeriBell (NASDAQ:CBLL)

Walleye Capital LLC purchased a new stake in shares of CeriBell (NASDAQ:CBLL) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 58,800 shares of the company’s stock, valued at approximately $1,522,000. Walleye Capital LLC owned 0.16% of CeriBell as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. FMR LLC bought a new position in shares of CeriBell during the 4th quarter valued at approximately $128,120,000. Vanguard Group Inc. bought a new position in CeriBell in the 4th quarter worth $18,015,000. Board of Trustees of The Leland Stanford Junior University purchased a new stake in CeriBell in the 4th quarter worth $16,143,000. Franklin Resources Inc. bought a new stake in CeriBell during the fourth quarter valued at about $12,460,000. Finally, Massachusetts Financial Services Co. MA purchased a new position in shares of CeriBell in the fourth quarter valued at about $10,750,000.

Analyst Ratings Changes

Several analysts recently issued reports on CBLL shares. LADENBURG THALM/SH SH began coverage on CeriBell in a research note on Friday, April 4th. They set a “buy” rating and a $32.00 target price on the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, CeriBell has an average rating of “Buy” and a consensus price target of $32.50.

CeriBell Stock Performance

Shares of CBLL opened at $14.85 on Friday. The business’s 50 day moving average price is $20.31. CeriBell has a 1 year low of $10.01 and a 1 year high of $32.75.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. As a group, equities analysts forecast that CeriBell will post -2.46 EPS for the current fiscal year.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.